Naproxol

Naproxol

SCHEMBL8471214

COc1ccc2cc(C(C)CO)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 1.00
AKR1C3 P42330 6/20 0.58
AKR1C2 P52895 6/20 0.58
PTGS2 P35354 3/20 0.58
PTGS1 P23219 3/20 0.58
TSHR P16473 2/20 0.58
CDC42 P60953 1/20 0.58
RAC1 P63000 1/20 0.58
CYP1A2 P05177 1/20 0.58
SLC22A6 Q4U2R8 1/20 0.58
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
CYP2C9 P11712 1/20 0.55
AKR1C1 Q04828 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALOX5 P09917 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naproxol SCHEMBL10395753 1.00 ABCB11 (1.00) ABCB11AKR1C3AKR1C2PTGS2PTGS1
Naproxol SCHEMBL30599771 1.00 ABCB11 (1.00) ABCB11AKR1C3AKR1C2PTGS2PTGS1
Naproxol SCHEMBL43203 1.00 ABCB11 (1.00) ABCB11AKR1C3AKR1C2PTGS2PTGS1
Naproxol SCHEMBL29979997 1.00 ABCB11 (1.00) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL11015086 0.97 ABCB11 (0.93) ABCB11AKR1C3AKR1C2PTGS2PTGS1
Naproxol SCHEMBL9451481 0.91 ABCB11 (0.82) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL9009741 0.84 ABCB11 (0.72) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL28346869 0.84 ABCB11 (0.72) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL14783039 0.83 ABCB11 (0.71) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL11806102 0.83 ABCB11 (0.71) ABCB11AKR1C3AKR1C2PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421200-B2 Manganese-catalysed hydrogenation of esters UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2025-09-23 US disclosed
CN-118215461-A Compositions and methods for reducing pigmentation 总医院公司 2024-06-18 CN disclosed
EP-3737663-B1 MANGANESE-CATALYSED HYDROGENATION OF ESTERS UNIV COURT UNIV ST ANDREWS (GB) 2023-02-22 EP disclosed
CN-115160123-A Method for preparing carboxylic acid compound by oxidizing alcohol with oxygen as oxidant under catalysis of copper 复旦大学 2022-10-11 CN disclosed
WO-2022206399-A1 COPPER CATALYSIS-BASED METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND BY MEANS OF ALCOHOL OXIDATION USING OXYGEN AS OXIDANT 复旦大学 2022-10-06 WO disclosed
US-20210053932-A1 MANGANESE-CATALYSED HYDROGENATION OF ESTERS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2021-02-25 US disclosed
EP-3737663-A1 MANGANESE-CATALYSED HYDROGENATION OF ESTERS University Court of The University of St Andrews (GB) 2020-11-18 EP disclosed
CN-111587238-A Manganese catalyzed ester hydrogenation 圣安德鲁斯大学董事会 2020-08-25 CN disclosed
CN-104402919-A Method for synthesis of chiral pinacol boron ester compound UNIV ZHEJIANG 2015-03-11 CN disclosed
CN-101486643-B Trans naproxen ester, optical isomer thereof, as well as preparation and use thereof UNIV HUNAN 2012-08-15 CN disclosed
US-5273993-A Antiarthritic agents; osteoporosis A. H. ROBINS COMPANY, INCORPORATED (US) 1993-12-28 US disclosed
US-5194446-A Antiarthritic agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-16 US disclosed
US-5192785-A Sulfamates as antiglaucoma agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-09 US disclosed
US-4980291-A TRANSESTERIFICATION IN PRESENCE OF FREE OR IMMOBILIZED PSEUDOMONOS FLUORESCENS OR HYDROLASES ISTITUTO GUIDO DONEGANI S.P.A. (IT) 1990-12-25 US disclosed
EP-0403185-A2 Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals A.H. ROBINS COMPANY, INCORPORATED (US) 1990-12-19 EP disclosed
EP-0386848-A1 Novel Exophiala species GIST-BROCADES N.V. (NL) 1990-09-12 EP disclosed
EP-0328125-A2 Process for the enzymatic separation of the optical isomers of racemic alpha-alkyl-substituted primary alcohols ISTITUTO GUIDO DONEGANI S.p.A. (IT) 1989-08-16 EP disclosed
US-4820717-A Antimicrobial aromatic derivatives substituted by an (omega amino) alkanol group and compositions containing them SANOFI (FR) 1989-04-11 US disclosed
US-4243665-A ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; ANALGESICS; ANTIPYRETICS SYNTHELABO (FR) 1981-01-06 US disclosed
US-3958012-A ANTIINFLAMMATORY, ANALGESIC AND ANTIPYRETIC ACTIVITY SYNTEX CORPORATION (US) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421200-B2 Manganese-catalysed hydrogenation of esters ADH5, HDHD5, ADH1A ABCB11 2228/4885AKR1C3 1642/4885AKR1C2 1320/4885
US-20210053932-A1 MANGANESE-CATALYSED HYDROGENATION OF ESTERS ADH5, HDHD5, ADH1A ABCB11 2228/4885AKR1C3 1642/4885AKR1C2 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.